These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 21074424)

  • 1. Design, synthesis and SAR of thienopyridines as potent CHK1 inhibitors.
    Zhao L; Zhang Y; Dai C; Guzi T; Wiswell D; Seghezzi W; Parry D; Fischmann T; Siddiqui MA
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7216-21. PubMed ID: 21074424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 1.
    Dwyer MP; Paruch K; Labroli M; Alvarez C; Keertikar KM; Poker C; Rossman R; Fischmann TO; Duca JS; Madison V; Parry D; Davis N; Seghezzi W; Wiswell D; Guzi TJ
    Bioorg Med Chem Lett; 2011 Jan; 21(1):467-70. PubMed ID: 21094608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based design of novel Chk1 inhibitors: insights into hydrogen bonding and protein-ligand affinity.
    Foloppe N; Fisher LM; Howes R; Kierstan P; Potter A; Robertson AG; Surgenor AE
    J Med Chem; 2005 Jun; 48(13):4332-45. PubMed ID: 15974586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 2.
    Labroli M; Paruch K; Dwyer MP; Alvarez C; Keertikar K; Poker C; Rossman R; Duca JS; Fischmann TO; Madison V; Parry D; Davis N; Seghezzi W; Wiswell D; Guzi TJ
    Bioorg Med Chem Lett; 2011 Jan; 21(1):471-4. PubMed ID: 21094607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyridyl aminothiazoles as potent inhibitors of Chk1 with slow dissociation rates.
    Dudkin VY; Rickert K; Kreatsoulas C; Wang C; Arrington KL; Fraley ME; Hartman GD; Yan Y; Ikuta M; Stirdivant SM; Drakas RA; Walsh ES; Hamilton K; Buser CA; Lobell RB; Sepp-Lorenzino L
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2609-12. PubMed ID: 22374217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors.
    Tao ZF; Wang L; Stewart KD; Chen Z; Gu W; Bui MH; Merta P; Zhang H; Kovar P; Johnson E; Park C; Judge R; Rosenberg S; Sowin T; Lin NH
    J Med Chem; 2007 Apr; 50(7):1514-27. PubMed ID: 17352464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design and optimization of 2-aminothiazole-4-carboxamide as a new class of CHK1 inhibitors.
    Huang X; Cheng CC; Fischmann TO; Duca JS; Richards M; Tadikonda PK; Reddy PA; Zhao L; Siddiqui MA; Parry D; Davis N; Seghezzi W; Wiswell D; Shipps GW
    Bioorg Med Chem Lett; 2013 May; 23(9):2590-4. PubMed ID: 23535330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of thioquinazolinones, allosteric Chk1 kinase inhibitors.
    Converso A; Hartingh T; Garbaccio RM; Tasber E; Rickert K; Fraley ME; Yan Y; Kreatsoulas C; Stirdivant S; Drakas B; Walsh ES; Hamilton K; Buser CA; Mao X; Abrams MT; Beck SC; Tao W; Lobell R; Sepp-Lorenzino L; Zugay-Murphy J; Sardana V; Munshi SK; Jezequel-Sur SM; Zuck PD; Hartman GD
    Bioorg Med Chem Lett; 2009 Feb; 19(4):1240-4. PubMed ID: 19155174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas.
    Oza V; Ashwell S; Almeida L; Brassil P; Breed J; Deng C; Gero T; Grondine M; Horn C; Ioannidis S; Liu D; Lyne P; Newcombe N; Pass M; Read J; Ready S; Rowsell S; Su M; Toader D; Vasbinder M; Yu D; Yu Y; Xue Y; Zabludoff S; Janetka J
    J Med Chem; 2012 Jun; 55(11):5130-42. PubMed ID: 22551018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological activity of 5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one-based potent and selective Chk-1 inhibitors.
    Wang L; Sullivan GM; Hexamer LA; Hasvold LA; Thalji R; Przytulinska M; Tao ZF; Li G; Chen Z; Xiao Z; Gu WZ; Xue J; Bui MH; Merta P; Kovar P; Bouska JJ; Zhang H; Park C; Stewart KD; Sham HL; Sowin TJ; Rosenberg SH; Lin NH
    J Med Chem; 2007 Aug; 50(17):4162-76. PubMed ID: 17658776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The discovery of potent and selective 4-aminothienopyridines as B-Raf kinase inhibitors.
    Tang J; Lackey KE; Dickerson SH
    Bioorg Med Chem Lett; 2013 Jan; 23(1):66-70. PubMed ID: 23218715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors.
    Schenkel LB; Huang X; Cheng A; Deak HL; Doherty E; Emkey R; Gu Y; Gunaydin H; Kim JL; Lee J; Loberg R; Olivieri P; Pistillo J; Tang J; Wan Q; Wang HL; Wang SW; Wells MC; Wu B; Yu V; Liu L; Geuns-Meyer S
    J Med Chem; 2011 Dec; 54(24):8440-50. PubMed ID: 22087750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based design of 3-aryl-6-amino-triazolo[4,3-b]pyridazine inhibitors of Pim-1 kinase.
    Grey R; Pierce AC; Bemis GW; Jacobs MD; Moody CS; Jajoo R; Mohal N; Green J
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3019-22. PubMed ID: 19414255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of thienopyridinones as Chk1 inhibitors.
    Song P; Peng P; Han M; Cao X; Ma X; Liu T; Zhou Y; Hu Y
    Bioorg Med Chem; 2014 Sep; 22(17):4882-92. PubMed ID: 25042558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of new highly potent imidazo[1,2-b]pyridazines targeting Toxoplasma gondii calcium-dependent protein kinase 1.
    Moine E; Dimier-Poisson I; Enguehard-Gueiffier C; Logé C; Pénichon M; Moiré N; Delehouzé C; Foll-Josselin B; Ruchaud S; Bach S; Gueiffier A; Debierre-Grockiego F; Denevault-Sabourin C
    Eur J Med Chem; 2015 Nov; 105():80-105. PubMed ID: 26479029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of 5-pyrrolopyridinyl-2-thiophenecarboxamides as potent AKT kinase inhibitors.
    Seefeld MA; Rouse MB; McNulty KC; Sun L; Wang J; Yamashita DS; Luengo JI; Zhang S; Minthorn EA; Concha NO; Heerding DA
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2244-8. PubMed ID: 19285393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and structure-activity relationship of 4-(1,3-benzothiazol-2-yl)-thiophene-2-sulfonamides as cyclin-dependent kinase 5 (cdk5)/p25 inhibitors.
    Malmström J; Viklund J; Slivo C; Costa A; Maudet M; Sandelin C; Hiller G; Olsson LL; Aagaard A; Geschwindner S; Xue Y; Vasänge M
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5919-23. PubMed ID: 22889803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of brain penetrant selective JNK inhibitors with improved pharmacokinetic properties for the prevention of neurodegeneration.
    Bowers S; Truong AP; Jeffrey Neitz R; Hom RK; Sealy JM; Probst GD; Quincy D; Peterson B; Chan W; Galemmo RA; Konradi AW; Sham HL; Tóth G; Pan H; Lin M; Yao N; Artis DR; Zhang H; Chen L; Dryer M; Samant B; Zmolek W; Wong K; Lorentzen C; Goldbach E; Tonn G; Quinn KP; Sauer JM; Wright S; Powell K; Ruslim L; Ren Z; Bard F; Yednock TA; Griswold-Prenner I
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5521-7. PubMed ID: 21813278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of chemically diverse Chk1 inhibitors by receptor-based virtual screening.
    Foloppe N; Fisher LM; Howes R; Potter A; Robertson AG; Surgenor AE
    Bioorg Med Chem; 2006 Jul; 14(14):4792-802. PubMed ID: 16574416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benzothiophene inhibitors of MK2. Part 1: structure-activity relationships, assessments of selectivity and cellular potency.
    Anderson DR; Meyers MJ; Kurumbail RG; Caspers N; Poda GI; Long SA; Pierce BS; Mahoney MW; Mourey RJ
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4878-81. PubMed ID: 19616945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.